On April 3, 2017 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, reported that a poster featuring data related to Five Prime’s unique discovery platform was presented today at the 2017 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in Washington, D.C (Press release, Five Prime Therapeutics, APR 3, 2017, View Source [SID1234518422]). The poster titled "Identification of Novel T Cell Co-Inhibitory and Co-Stimulatory Receptors from Screening a Comprehensive Library of Extracellular Proteins" is available at View Source Schedule your 30 min Free 1stOncology Demo! "We have generated a comprehensive library of essentially all human extracellular proteins and have used this library to screen for new agents that modulate the function of various immune cell subsets," said Luis Borges, Ph.D., Senior Vice President of Research at Five Prime. "Taken together, we have developed robust in vitro and in vivo platforms that allow us to discover new immuno-oncology targets that we believe will help address the needs of cancer patients who fail to respond to current immunomodulatory therapies."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Five Prime has developed multiple sophisticated in vitro, in vivo, and biophysical assay systems for screening its comprehensive library of human extracellular proteins to identify novel therapeutics that can reprogram immune cells in the tumor microenvironment.
These multiple approaches include:
In vitro screens of primary human effector and regulatory T cells to identify novel proteins that can modulate T cell activation and suppression.
Screening subsets of the discovery library in four distinct syngeneic mouse tumor models (either as single agents, or in combination with checkpoint blockade or a vaccine) to identify targets that can modulate an anti-tumor immune response in vivo.
Performing a combinatorial biophysical screen for extracellular protein-protein interactions within a set of approximately 700 predicted immune-related transmembrane proteins to identify novel receptor-ligand interaction networks.
As a result of these screens that combine data from multiple screening approaches, Five Prime has prioritized a series of new targets for validation and potential generation of novel immuno-oncology therapeutics.